Calquence generic
Calquence is an anti-cancer drug owned by Astrazeneca. It contains acalabrutinib maleate and is available in the form of tablets for oral administration. It was first authorized for market use on 03 August, 2022 and currently holds 7 patents, none of which have expired.
When will Calquence generic be available?
The generic version of Calquence may become available after 01 July, 2036, which is after the expiry date of its last patent.
Calquence uses
Calquence is primarily used for the treatment of adult patients with conditions such as mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic leukemia. The drug's effectiveness is attributed to its active ingredient, Acalabrutinib, which is administered twice daily in doses of 100mg. For previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia, it is used in combination with obinutuzumab.
Calquence patent expiration
Astrazeneca's Calquence holds a total of 7 patents, none of which have expired. The last patent for Calquence is expiring on 01 July, 2036. The approval for generic versions could be possible after this date. Below are the details of the patent: